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SURVEILLANCE OF MULTIDRUG-RESISTANT UROPATHOGENIC ESCHERICHIA 
COLI IN HOSPITALIZED PATIENTS AND COMMUNITY SETTINGS IN THE SOUTH 
OF LEBANON 
Abstract 
Urinary Tract Infection (UTI) is one of the common infectious diseases in both hospitals as well as 
community settings; they are recognized to be among the most serious worldwide bacterial infections 
impacting 150 million people globally every year. The purpose of this study was to assess the changing 
antibiotics resistance profile for uropathogenic Escherichia coli isolated from community and hospital 
setting over a period of time (2018–2019) with a special emphasis on ESBL/MDR producing Escherichia 
coli. A descriptive retrospective study was conducted among patients with uropathogenic Escherichia 
coli from both community and hospital settings in south Lebanon. Out of 863 patients with positive 
uropathogenic Escherichia coli, 451 (52.25 %) comes from the community while 412 (47.74 %) came from 
the hospital settings. Almost 60.83 % are not Extended Spectrum Beta-Lactamases (ESBL), 31.4 % ESBL, 
and 7.76 % Multiple drug resistance (MDR). The majority of urinary tract infections are related to the 
female population (78.21 %). The most vulnerable age for both gender to develop UTI belong to elderly 
population (>64 years) which account 37.19 % of all isolates. Statistically, we observed a high resistance 
rate toward all antibiotics using in the treatment of urinary tract infections such as Cefixime (45.30 %), 
Sulfamethoxazole (44.95 %), Ciprofloxacin (38.23 %) and Augmentin (38.93 %). A statistically significant 
association was observed between risk factors for hospitalized patients and all age categories with (P < 
0.05). Susceptibility profiles are critical to be evaluated in countries such as Lebanon where excessive use 
of antibiotics is observed at all levels. Therefore, this finding is useful for the determination of appropriate 
antimicrobial treatment in UTI patients that are caused by Escherichia coli and to follow the antimicrobial 
stewardship program to reduce the rate of resistance toward antibiotics. 
Keywords 
Urinary tract infection, Escherichia coli, Multidrug resistance, Antimicrobial resistance. 
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1. INTRODUCTION 
        Urinary Tract Infections (UTIs) constitute the main cause of morbidity and mortality 
worldwide (Foxman, 2010).     The key cause of UTIs is reported to be Escherichia coli (E. coli) 
(Farajnia et al., 2009), and the uropathogenic E. coli (UPEC), a subset of pathogenic extra-intestinal 
E. coli (ExPEC) group, is associated with causing more than 80% of all UTIs (Ronald, 2002). It has 
been guesstimate that 150 million UTIs occur per year globally (Stamm & Norrby, 2001). UTI 
happens eight times more often in females than in males, and about 50-60% of women report at least 
one UTI in their lifespan (Foxman et al., 2000; Rahn, 2008; Al-Badr and Al-Shaikh, 2013). In the 
US, UTIs are accountable for >7 million physician visits yearly and 15% of all community-prescribed 
antibiotics, with similar statistics in some European countries (Bonkat et al., 2017). E. coli causes the 
majority of UTIs and pyelonephritis, where the host vaginal or fecal microbiota is the most common 
source for these strains—termed Uropathogenic E. coli—although UPECs are not necessarily the 
predominant clones from these reservoirs.                                                            
        However, there is a frightening level of antimicrobial resistance developing in UTI 
pathogens as a consequence of random and global use of antibiotics. Bacteria producing extended-
spectrum beta-lactamases (ESBLs), exhibiting resistance to most antibiotics except for the 
carbapenem group, are steadily increasing in the population (Bonkat et al., 2017; Oteo et al., 2010). 
ESBLs are enzymes that break down commonly used antibiotics, such as penicillins and 
cephalosporins, making them ineffective. ESBL-producing Enterobacteriaceae often cause infections 
in otherwise healthy people. Over the past twenty years, the antimicrobial resistance of ExPEC to 
first-line antibiotics, such as amoxicillin and ciprofloxacin has escalated markedly (Foxman, 2010). 
Additionally, an increased extended-spectrum β-lactamase (ESBL) carriage has been announced 
among ExPEC strains (Pitout et al., 2005b). As reported in 2008, E. coli sequence type 131 (E. coli 
ST131) was described among ESBL-producing E. coli in many continents throughout the world, and 
it has distributed to become the preponderant ExPEC clone that drives multidrug resistance (MDR) 
universally (Nicolas-Chanoine et al., 2014). MDR is when a single bacterium is resistant to more than 
one antibiotic it is said to be multidrug-resistant. Antimicrobial resistance is currently one of the main 
issues in public health (Cassini et al., 2019). The prevalence of multidrug-resistant (MDR) bacteria 
has risen significantly in recent decades, and the World Health Organization (WHO) has incorporated 
antimicrobial resistance in its list of 10 world threats to public health. Infections by MDR organisms 
are especially important in health care settings. However, they have also increased in frequency in 
community settings (Kaarme et al., 2018). These infections have a poorer prognosis because of the 
delay in the initiation of suitable antibiotic therapy and the need for alternative antibiotics, which are 
usually less effective and are less secure (Chiotos et al., 2016; Folgori et al.,2017).  
       The increase of antibiotic resistance and development of multi-drug resistant (MDR) 
pathogens in the course of UTI is correlated with high rates of inadequate antibiotic empirical 
therapies prescribed without checking for antibiotic susceptibility testing and finally result in an 
ineffective UTI treatment (Adamus-Białek 2018). As a consequence, surveillance and antimicrobial 
stewardship programs have been directed to optimize the prevention and control of infections by 
lowering antibiotic resistance rates in hospitals (CDC, 2013). 
         According to a study previously carried out in Beirut (Daoud & Afif, 2011),  E. coli was 
the most recurrent isolate (60.64% of the total isolates) and an increase in the production of ESBL 
was noticed between the years 2000 and 2009 (2.3% to 16.8%). Unfortunately, very limited data 
concerning UTIs is obtainable from other regions of the country. The purpose of this study was to 
assess the changing antibiotics resistance profile for uropathogenic Escherichia coli isolated from 
community and hospital setting over a period of time (2018–2019) with a special emphasis on 
ESBL/MDR producing Escherichia coli. The findings of this study will redound to the benefit of the 
Lebanese healthcare society by showing the real fact of the antibiotics' resistance in the hospital and 
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2. METHODOLOGY 
        The aim of this study was to assess the changing antibiotics resistance profile for 
uropathogenic Escherichia coli isolated from community and hospital setting over a period of time 
(2018–2019) with a special emphasis on ESBL/MDR producing Escherichia coli. A descriptive cross-
sectional research design was adopted. This study was conducted in laboratory department of one 
hospital in South, Lebanon. An official permission to conduct this study was obtained from the 
responsible authorities referred to institutional review board (IRB) at Beirut Arab University, and the 
ethical committee at the relevant clinical site after explaining the aim of the study, where the 
anonymity and confidentiality of the data have been guaranteed to be maintained. All Patients (863) 
who have positive UPEC belong to any age group and gender were included in the study. Patient that 
have urinary tract infection caused by other bacteria than Escherichia coli were excluded. Hospital 
based UTI was defined to be prevalent after 48 hours of admission. Data was collected retrospectively 
for the two years 2018/2019. Nine hundred and thirteen cases were recorded to be eligible to be 
included in the research, however the researchers were able to access the files of 863 patients therefore 
a rate of 94.52%. The Statistical Package for Social Science (Corp, 2013) was used to analyze the 
data. Descriptive statistics were utilized to describe the characteristics of the patients that suffer from 
positive UPEC. The inferential statistics were used to test the relationship between variables.  
 
3. RESULTS 
3.1. Socio-Demographic Characteristics Of Patient With Positive UPEC  
       The study included eight hundred thirty-six patients (N= 863), where 675 (78.21 %) 
of them were females while 188 (21.78 %) of them were males. With regard to the age categories 
of patients, a total of 321 (37.19 %) samples were collected from the elderly, 305 (35.34 %) 
samples belong to adults population, and 237 (27.46 %) were obtained from children. In addition, 
412 (47.74 %) are hospitalized admitted patient (inpatient) while 451 (52.25 %) came from the 






                                                    Table 1: Sociodemographic characteristics 
 















        
 Moreover, with respect to setting or location, inpatients females are at higher risk for the 
development of UTIs than males respectively (295, 71.60 %; VS 117, 28.39 %).Also, outpatient 
is higher in female than male respectively (380, 84.25 %; VS 71, 15.74 %).On the other hand, a 
total of 197 (83.12 %) were collected from female children, 251 (82.29 %) collected from adult 
females, and 227 (70.71 %) collected from an elderly female. While, 40 samples (16.87 %) 
collected from male children, 54 (17.70 %) from adult males and 94 (29.28 %) from the elderly 
males (Table 2). 
 
Table 2: Distribution of UPEC by age category and setting with respect to gender 
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3.2. Prevalence Of ESBL and MDR Production Among UPEC 
        A descriptive analysis was carried out to assess the prevalence of MDR and ESBL 
production among UPEC. From 863 patients with positive uropathogenic Escherichia coli, we 
have 525(60.83 %) samples are non ESBL, 271(31.4 %) ESBL & 67(7.76 %) sample are MDR. 
Also, the most associated group for both ESBL and MDR are from the female population (200 
samples, 73.8 % VS; 47 samples, 70.14 %) compared to male (71 samples, 26.19%, VS; 20 
samples, 29.85 %) respectively with P-value = 0.011 which is significantly associated with a P 
value less than 0.05. On the other hand, ESBL and MDR are significantly higher in the 
hospitalized patient (inpatient) (156 samples, 37.86%; 43 samples, 10.43%) compared to 
outpatient (115 samples, 25.49%; 24 samples, 5.32%) respectively with P value=0.000* (Table 
3). 
 
Table3.Prevalence of ESBL and MDR producing among UPEC 
























3.3. Antimicrobial Profile  
        A descriptive analysis was also carried out to determine antimicrobial susceptibility 
for UPEC strains. The results of antibiotic susceptibility showed that the highest resistance rate 
was against amoxicillin (73.58%) followed by cefuroxime (55.38%), tetracycline (50.28%), 
Cefixime (45.3 %), Sulfamethoxazole (44.95 %) and Norfloxacin (40.55 %). On the other hand, 
the highest susceptibility was toward Colistin (99.07 %), Imipenem (99.18 %), Meropenem 
(98.95 %), Nitrofurantoin (98.95 %), Fosfomycin (98.72 %), Pipracillintazobactam (91.42 %), 
Amikacin (91.19 %) and Gentamicin (66.85 %) (Table 4). 
 
Table 4: Antimicrobial susceptibility for UPEC strains  
 
Antibiotics Resistance Intermediate Susceptible 
Amoxicillin 636(73.69) 69(7.99) 158(18.30) 
Augmentin 336(38.93) 239(4.51) 28(33.37) 
Cefixime 391(45.30) 30(3.47) 441(51.10) 
Cefotaxime 339(39.28) 5(0.57) 519(60.13) 
Cefoxitine 89(10.31) 82(9.50) 692(80.18) 
Ceftriaxone 339(39.28) 2(0.23) 522(60.48) 
Ceftazidime 342(39.26) 7(0.81) 514(59.55) 
Cefuroxime 478(55.38) 4(0.46) 381(44.14) 
Ciprofloxacin 330(38.23) 40(4.63) 493(57.12) 
Norfloxacin 350(40.55) 38(4.40) 475(55.04) 
Levofloxacin 324(37.54) 30(3.47) 509(58.98) 
Amikacin 32(3.70) 44(5.09) 787(91.19) 
Gentamicin 187(21.66) 99(11.47) 577(66.85) 
Nitrofurantoin 9(1.04) 0(0) 854(98.95) 
Fosfomycin 22(2.54) 0(0) 852(98.72) 
PipracillinTazobactam 33(3.82) 41(4.75) 789(91.42) 
Colistin 8(0.92) 0(0) 855(99.07) 
Imipenem 6(0.69) 1(0.11) 856(99.18) 
Meropenem 8(0.92) 1(0.11) 854(98.95) 
Sulfamethoxazole 388(44.95) 2(0.23) 473(54.80) 
Tetracycline 434(50.28) 19(2.2) 410(47.5) 
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3.4. Comparison of Antimicrobial Resistance Pattern Among UPEC for Year 2018 and 
2019 
       Descriptive analysis was made to make a comparison between the years 2018 and 
2019. For the year 2018, we have 384 patients with uropathogenic Escherichia coli while in 2019 
we have 479 patients with uropathogenic Escherichia Coli. Based on the resistance profile for the 
year 2018 and 2019, we see an increase resistance toward all antibiotics that’s used to treat urinary 
tract infection such as Cefixime (41.66 %, VS 48.22 %) ,Augmentin (36.45 % ,VS 40.9 %),  
Sulfamethoxazole (42.18 %, VS 47.18 %), Gentamicin (16.92 %, VS 25.05 %), Nitrofurantoin 
(0.78 %, VS 1.25 %), Fosfomycin (2.08 %, VS 2.92 )and Levofloxacin (36.97 %, VS 37.99 %) 
respectively (Table 5). 
 
 
        Table 5: Comparison of Antimicrobial profile for the years 2018 and 2019 
 
 2018   2019   
Antibiotics Resistance Intermediate Susceptible Resistance Intermediate Susceptible 
Amoxicillin 278(72.39) 31(8.07) 75(19.53) 357(74.53) 38(7.93) 83(17.32) 
Augmentin 140(36.45) 107(27.86) 137(35.67) 196(40.90) 132(27.55) 151(31.52) 
Cefixime 160(41.66) 12(3.12) 211(54.94) 231(48.22) 18(3.75) 230(48.01) 
Cefotaxime 141(36.71) 1(0.26) 242(63.02) 198(41.33) 4(0.83) 277(57.82) 
Cefoxitine 38(9.89) 32(8.33) 314(81.77) 51(10.64) 50(10.43) 378(78.91) 
Ceftriaxone 140(36.45) 4(1.04) 240(62.5) 199(41.54) 2(0.41) 278(58.03) 
Ceftazidime 142(36.97) 3(0.78) 239(62.23) 200(41.75) 4(0.83) 275(57.41) 
Cefuroxime 169(51.04) 2(0.52) 186(49.21) 282(58.87) 2(0.41) 195(40.70) 
Ciprofloxacin 147(38.28) 18(4.68) 219(57.03) 182(37.99) 22(4.59) 274(57.20) 
Norfloxacin 162(42.18) 15(3.90) 207(53.90) 188(39.24) 23(4.80) 268(55.94) 
Levofloxacin 142(36.97) 14(3.64) 228(59.37) 182(37.99) 16(3.34) 281(58.66) 
Amikacin 10(2.60) 13(3.38) 361(94.01) 22(4.59) 31(6.47) 526(88.93) 
Gentamicin 65(16.92) 34(8.85) 285(74.21) 120(25.05) 65(13.56) 292(60.96) 
Nitrofurantoin 3(0.78) 0(0) 381(99.21) 6(1.25) 0(0) 473(98.74) 
Fosfomycin 8(2.08) 0(0) 376(97.91) 14(2.92) 0(0) 464(96.86) 
PipracillinTazobactam 13(3.38) 23(5.98) 348(90.62) 20(4.17) 18(3.75) 439(91.64) 
Colistin 0(0) 0(0) 384(100) 8(1.67) 0(0) 471(98.32) 
Imipenem 0(0) 0(0) 384(100) 6(1.25) 1(0.20) 472(98.53) 
Meropenem 0(0) 0(0) 284(100) 8(1.67) 1(0.20) 470(98.12) 
Sulfamethoxazole 162(42.18) 2(0.52) 220(57.29) 226(47.18) 0(0) 253(52.81) 
Tetracycline 196(51.04) 16(4.16) 172(44.79) 238(49.68) 3(0.62) 238(49.68) 
 
3.5. Susceptibility Profile For ESBL And NON-ESBL Escherichia Coli Isolated From 
Urine  
       A descriptive analysis was also carried out to determine the susceptibility profile of 
ESBL Escherichia coli isolated from the urinary tract. Among all antibiotics tested in this study 
for extended-spectrum beta-lactamase (ESBL), Carbapenem, Nitrofurantoin, and Fosfomycin 
was the most active against Escherichia coli isolates, also 90.77 % to piperacillin-tazobactam, 
83.02 % to Amikacin and 53.87 % to gentamicin. Out of 271 ESBL producing Escherichia .coli 
isolates, 98.52% were resistant to amoxicillin, 66.05 % to Norfloxacin, 64.20% to Ciprofloxacin, 
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Table 6: Antimicrobial profile for ESBL producing UPEC 
 
Antibiotics Resistance Intermediate Susceptible 
Amoxicillin 267(98.52) 0(0) 4(1.47) 
Augmentin 169(62.36) 94(34.68) 8(2.95) 
Cefixime 267(98.52) 1(0.36) 3(1.10) 
Cefotaxime 266(98.15) 1(0.36) 4(1.47) 
Cefoxitine 2(0.73) 42(15.49) 227(8.11) 
Ceftriaxone 267(98.52) 0(0) 4(1.47) 
Ceftazidime 267(98.52) 0(0) 4(1.47) 
Cefuroxime 268(98.89) 0(0) 3(1.10) 
Ciprofloxacin 174(64.20) 10(3.69) 87(32.10) 
Norfloxacin 179(66.05) 11(4.05) 81(29.88) 
Levofloxacin 171(63.09) 10(3.69) 90(33.21) 
Amikacin 17(6.27) 29(10.70) 225(83.02) 
Gentamicin 94(34.68) 31(11.43) 146(53.87) 
Nitrofurantoin 2(0.73) 0(0) 269(99.26) 
Fosfomycin 9(3.32) 0(0) 262(96.67) 
PipracillinTazobactam 6(2.21) 19(17.01) 246(90.77) 
Colistin 1(0.36) 0(0) 270(99.63) 
Imipenem 1(0.36) 0(0) 270(99.63) 
Meropenem 1(0.36) 0(0) 270(99.63) 
Sulfamethoxazole 153(56.45) 1(0.36) 106(39.11) 
Tetracycline 170(62.73) 8(2.95) 93(34.31) 
 
 
3.6. Distribution Of Antimicrobial Profile For MDR Escherichia Coli Isolates From 
Urine  
       A descriptive analysis was also carried out to determine the Distribution of Multi-drug 
resistant (MDR) Escherichia coli isolates among urine. The results show that Multidrug-resistant 
isolates were resistant 100% to Cephalosporin’s & amoxicillin, 77.61% to Trimethoprim-
sulfamethoxazole, 71.64% to Norfloxacin, and 67.16 % to Ciprofloxacin & levofloxacin. 
Moreover, the distribution of ciprofloxacin (231 samples, 70.21 %) and levofloxacin (227 
samples, 70.06 %) resistance was significantly higher among female than male gender with P-
value =0.000*. Also, UPEC isolates from hospital-acquired infection was associated with 
Ceftazidime (P=0.000*) and MDR phenotype in a hospitalized patient more than in the 
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Table 7: Antimicrobial profile for MDR Escherichia coli isolated from urine 
 
Antibiotics Resistance Intermediate Susceptible 
Amoxicillin 67(100) 0(0) 0(0) 
Augmentin 67(100) 0(0) 0(0) 
Cefixime 66(98.50) 0(0) 1(0.19) 
Cefotaxime 66(98.50) 0(0) 1(0.19) 
Cefoxitine 63(94.02) 3(0.57) 1(0.19) 
Ceftriaxone 66(98.50) 0(0) 1(0.19) 
Ceftazidime 64(95.52) 2(0.38) 1(0.19) 
Cefuroxime 66(98.50) 0(0) 1(0.19) 
Ciprofloxacin 45(67.16) 5(0.95) 17(3.23) 
Norfloxacin 48(71.64) 2(0.38) 17(3.23) 
Levofloxacin 45(67.16) 3(0.57) 19(11.23) 
Amikacin 4(5.97) 4(5.97) 59(5.90) 
Gentamicin 30(44.77) 6(1.14) 31(5.90) 
Nitrofurantoin 3(4.47) 0(0) 64(12.19) 
Fosfomycin 2(2.98) 0(0) 65(12.38) 
PipracillinTazobactam 19(28.35) 11(2.09) 37(7.04) 
Colistin 4(5.97) 0(0) 63(12) 
Imipenem 3(4.47) 1(0.19) 63(12) 
Meropenem 4(5.97) 0(0) 63(12) 
Sulfamethoxazole 52(77.61) 0(0) 15(2.85) 
Tetracycline 45(67.16) 2(0.38) 20(3.80) 
 
3.7. Results of Chi-square 
        A Chi-Square test was carried out to determine if there is an association between age 
and gender on one hand and the location on the other. During the study, females (675 samples, 
78.21 %) were the most affected group of patients with P-value <0.05 as compared to males (188 
samples, 21.78 %). Moreover, most of the urinary tract infection was detected in a community 
setting (451 samples, 52.25 %) while 412 were obtained from hospital-acquired infection (47.74 
%). Also, females of age group 18-64 years (251 samples, 37.18 %) are more prone to develop 
urinary tract infections than males (54 samples, 28.72 %) with highly significant P value (< 0.05). 
However, females were correlated with community-acquired urinary tract infection of both age 
groups (<18 & 18-64) and with hospital-acquired infection of age group (>64) with P-value < 
0.05. Therefore, the results showed that there is a significant relationship between the age and 
gender where a significant-value of p = 0.000* was recorded. In addition, another highly 
significant association was noted between the age and location of where a p-value of p = 
0.000*was recorded (Table 8). 
 
Table 8: Results of association between age with gender and setting 
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Another chi-Square test was carried out to determine if there is an association between 
antibiotic resistance and gender on one hand and the location on the other. High frequency of 
resistance was observed toward Amoxicillin (73.69 %), cefuroxime (55.38 %), tetracycline 
(50.98 %), cefixime (45.30 %), TM/SMX (44.95 %), and norfloxacin (40.55 %). From twenty-
one different antibiotics tested, highly susceptible isolates were toward imipenem, meropenem, 
colistin, nitrofurantoin, fosfomycin, and amikacin with low resistance rate respectively (0.69 %, 
0.92 %, 0.92 %, 1.04 %, 2.54 %, and 3.7 %). Among 863 we have 67 isolates were related to 
multidrug-resistant organisms MDR (7.76 %). MDR organisms were highly resistant toward 
amoxicillin and cephalosporin, TM/SMX (77.61 %), tetracycline (67.67 %) and gentamicin 
(44.77 %). Moreover, the fluoroquinolone-resistant strain showed MDR. And the percentage for 
resistance toward these families was 71.64 % to norfloxacin 67.16 % to ciprofloxacin and, 67.16 
% to levofloxacin. Moreover, the distribution of quinolones family that includes (ciprofloxacin, 
norfloxacin, and levofloxacin) resistance was significantly higher among male than female 
gender (52.12 %, 53.19 %, 51.59 %, P=0.000*, VS 34.37 %, 37.03%, 33.62%) and also, these 
quinolones antibiotics are higher in hospitalized patient than in community-acquired infection 
respectively (53.88 %, 54.61 %, 53.15 %, P=0.000* VS, 23.94 %, 27.71 %, 23.28 %). Therefore, 
the results showed that there is significant association between gender and antibiotics include: 
cefotaxime (p=0.009), cefoxitine (0.000*), ceftriaxone (p=0.012), ceftazidime (p=0.012) and 
quinolones family with p value =0.000*, amikacin (p=0.047) and gentamicin (p= 0.000*). Also, 
the results of this analysis showed that there is a significant relationship between location and 
antibiotics that include: Augmentin (p=0.004), cefixime (0.000*), cefotaxime (p=0.000*), 
cefoxitine (p=0.002), ceftriaxone, ceftazidime, cefuroxime, tetracycline ciprofloxacin, 
norfloxacin and levofloxacin with p value =0.000*, gentamicin (p=.008) (Table 9). 
 
Table 9: Results of association between antibiotics with gender and setting 
 













Amoxicillin 636 (73.69) 67(100) 144(76.59) 492(72.88) 0.58 321(71.17) 315(76.45) 0.091 
Augmentin 336(38.93) 67(100) 76(40.42) 260(38.51) 0.278 155(34.36) 181(43.93) 0.004 
Cefixime 391(45.30) 66(98.5) 101(53.72) 290(42.96) 0.068 172(37.13) 219(53.15) 0.000 
Cefotaxime 339(39.28) 66(98.5) 91(48.40) 248(36.74) 0.009 139(30.82) 200(48.54) 0.000 
Cefoxitine 89(10.31) 63(94.02) 26(13.82) 63(9.33) 0.000 35(7.76) 54(13.10) 0.002 
Ceftriaxone 339(39.28) 66(98.5) 91(48.40) 248(36.74) 0.012 139(30.82) 200(48.54) 0.000 
Ceftazidime 342(39.26) 64(95.52) 92(48.93) 250(37.03) 0.012 139(30.82) 203(49.27) 0.000 
Cefuroxime 478(55.38) 66(98.5) 116(61.70) 362(53.62) 0.095 223(49.44) 255(61.89) 0.000 
Ciprofloxacin 330(38.23) 45(67.16) 98(52.12) 232(34.37) 0.000 108(23.94) 222(53.88) 0.000 
Norfloxacin 350(40.55) 48(71.64) 100(53.19) 250(37.03) 0.000 125(27.71) 225(54.61) 0.000 
Levofloxacin 324(37.54) 45(67.16) 97(51.59) 227(33.62) 0.000 105(23.28) 219(53.15) 0.000 
Amikacin 32(3.70) 4(5.97) 8(4.25) 24(3.55) 0.047 15(3.32) 17(4.12) 0.369 
Gentamicin 187(21.66) 30(44.77) 71(37.76) 116(17.18) 0.000 79(17.51) 108(26.21) 0.008 
Nitrofurantoin 9(1.04) 3(4.47) 2(1.06) 7(1.03) 0.974 7(1.55) 2(0.48) 0.123 
Fosfomycin 22(2.54) 2(2.98) 2(1.06) 20(2.96) 0.144 11(2.43) 11(2.66) 0.830 
PipracillinTazobactam 33(3.82) 19(28.35) 8(4.25) 25(3.70) 0.673 13(2.88) 20(4.85) 0.279 
Colistin 8(0.92) 4(5.97) 1(0.53) 7(1.03) 0.523 4(0.88) 4(0.97) 0.898 
Imipenem 6(0.69) 3(4.47) 1(0.53) 5(0.74) 0.830 4(0.88) 2(0.48) 0.451 
Meropenem 8(0.92) 4(5.97) 2(1.06) 6(0.88) 0.849 4(0.88) 4(0.97) 0.573 
Sulfamethoxazole 388(44.95) 52(77.61) 85(45.21) 303(40.88) 0.756 183(40.57) 205(49.75) 0.025 
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3.8. Risk factor for UPEC in Hospitalized Patient 
Descriptive and inferential analysis chi-square was also carried out to determine the risk 
factors for acquiring uropathogenic Escherichia coli in hospitalized patients according to gender 
and age group. Out of N=412 hospitalized patients (inpatient), where 294 (71.35 %) of them were 
female while, 118 (28.64 %) of them belong to a male. With regard to gender, females are more 
prone to develop urinary tract infection than males as see in table menopausal female (204 
samples, 69.38 %, P=0.000*) which is significantly associated with urinary tract infection. Also, 
another risk factor such as diabetic patient was higher in female than male (34.01 %, VS 16.10 
%) with p value=0.000* also the previous hospitalization is significantly associated with UTI 
development especially in the female population than male respectively (64.28 %, VS 50.84 %) 
with P-value =0.012. While there is no association between gender and previous antibiotics use 
with (P Value=0.861). On the other hand, with regard to the age category, there is a significant 
association between older age category (>64 years) and menopause (166 samples, 70.33 %), 
diabetic (98 samples, 41.52 %), previous hospitalization (166 samples, 70.33 %) & previous 
antibiotics (169 samples, 71.61 %) however, all of them with P-value =0.000* which is less than 
0.05 and therefore it’s strongly associated (Table 10). 
 
Table10: Risk factor for UPEC in hospitalized patient 
 







































































      This chapter provides a general discussion of the study findings, which compares our results 
to that of various other studies that have to investigate to evaluate UPEC. However, in south Lebanon, 
there are no studies on microbiological surveillance of multidrug-resistant UPEC at hospitals and 
community settings or related topics. Because urinary tract infection is one of the most common 
medical problems affecting the population. This retrospective study aim to describe the prevalence of 
uropathogenic Escherichia coli (N=863 isolates) from the community (451 isolates ) and hospital-
acquired (412 isolates) urinary tract infections and their antibiotics resistance profile between the 
years  2018 and 2019 at the capital hospital ( Alnajdi hospital) in the Nabatieh area at the south of 
Lebanon. 
       In the present study, 863 patients with positive uropathogenic Escherichia coli were 
reported, 675 cases (78.21%) were female, while 188 cases (21.78%) were male (P<0.05). Gender 
and urinary tract infections were found to have a major correlation. This result is consistent with 
Mahesh et al (Mahesh et al., 2010), demonstrating that female urinary tract infection was higher than 
males (65 %, 35% respectively). With regard to the age category, the female population was higher 
than the male population throughout all age groups, studies have demonstrated that the higher 
prevalence of urinary tract infection in females can be attributed to many factors, such as the 
anatomical factor suggesting that urethra in females is shorter than in males and closer to anus, 
increasing the probability that Escherichia coli bacteria can be easily translatable to the bladder 
(Ghanbari et al. 2017; Tabasi et al., 2015) Poor hygiene and sexual activity as well as contraception 
use (John et al., 2016). This finding is consistent with previous studies in Lebanon and other countries 
that in our study, the prevalence of urinary infection toward females was higher than those of males 
within all age groups (Daoud, 2011; Tajbakhsh et al., 2015; Ghanbari et al., 2017; Tabasi et al., 2015). 
In addition, UTIs in our sample are more prevalent throughout the older age group (> 64 years), which 
is 37.19 %; increasing risk of prostate problem prevalence in males and diabetes mellitus are willing 
to increase the incidence of UTI in elderly patients (Mahesh et al., 2010). 
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 The diagnosis and treatment of diseases in this age group (>64 years) have become more 
important because of the growing elderly population worldwide. UTI is a major cause of mortality 
and morbidity in older patients.  Urinary tract infection is amongst the most considerable causes of 
sepsis in elderly patients, with a mortality rate of 33 percent associated with urosepsis. (Gbinigie et 
al., 2018). Visits to the outpatient clinic by the elderly population due to Urinary tract infection were 
noted to be three times greater than those in the younger population (Cortes-Penfield et al., 2017). 
This was typically associated with age-related bladder malfunction, urethral catheterization, and 
blood vessel obstruction related to benign prostatic hyperplasia, especially in males. Additionally, 
due to repeated antibiotic therapies, resistance to antibiotics is higher in older patients along with 
young patients (Gbinigie et al., 018). 
       The study revealed the prevalence of UPEC's broad spectrum beta-lactamase phenotype 
was (31.4 %) but was low in this study for multidrug-resistant (8 %) like other Mexican studies 
recording (16.4 percent) of MDR strain (Ochoa et al., 2016). While (Paniagua –Contreras et al., 
2017)'s research has shown 97 percent of multidrug-resistant strains. The burden of ESBL in 
community-acquired infections is also increasing (Rodríguez-Bano et al., 2008) noted that older age, 
men, DM existence, and fluoroquinolone utilization over the last two months are risk factors in 
community-acquired ESBL-producing E.  coli infection. In response, serious adverse effects such as 
fluoroquinolone-induced QT prolongation, delirium, and seizures were recorded by the United States 
Food and Drug Administration in May 2016 (Gbinigie et al., 2018). Therefore the use of 
fluoroquinolone must be restricted in patients who are at high risk. The involvement of ESBL in this 
research was greater than in other studies (Coskun USS, Coskun G, 2015; Asgin & Satilmis, 2019; 
Duman et al., 2010). This may be attributable to our patient group comprising of elderly patients and 
fluoroquinolone being unnecessary prescribed. 
      In this study, all species of Escherichia coli (N=863) were resistant to amoxicillin (73.58 
percent) suggesting a careful use of these antibiotics to treat urinary tract infection. Resistant 
Escherichia coli to the family penicillin community was on a higher side in different parts of the 
world, and it is growing day by day (Olowe et al., 2007). Resistance to the combination amoxicillin-
CA (Augmentin 38.93 percent) was also high like other studies that posted similar findings (Drawz 
& Bonomo, 2010). The degree of resistance in E.coli strains to amoxicillin-clavulanic acid in elderly 
patients was 39.58 %. In agreement with the research by Ulug et al. (Ulug &Gul, 2012), this incidence 
was stated to be 33 percent in elderly patients. In addition, the resistance rates to third-generation 
cephalosporins include cefixime in E. coli strains were 37%, high resistance to cefixime may be 
explained by the fact that our research group composed of elderly patients. In general, antibiotic 
resistance in the elderly population is perceived to be higher relative to that in the young. It could be 
due to excessive antibiotic (Palacios-Ceña et al., 2017). 
       For this research project, the rate of TMP-SMX resistance in E. coli was 35%. Likewise, 
high resistance rates were recorded in the Brazilian (35 percent) (Marques, 2012) and the US (60 
percent) studies (Das et al., 2009). In contrast, Fagan et al.'s analysis (Fagan et al., 2015) (Norway) 
noticed resistance levels to be 24 percent. However, Over 44 percent of isolates displayed TM-SMX 
resistance, which is prescribed as the first option for UTI treatment (Ali et al., 2014). Similar results 
have been recorded in recent studies (Pniagua-Contreras et al., 2017). In particular, TM-SMX's 
resistance rate increased from 2018 (42.18%) to 2019 (47.18%) in my study so, the rise in resistance 
indicates that great caution should be exercised when deciding to use this antibiotic. 
        The rise in fluoroquinolone usage (Ciprofloxacin, Levofloxacin & Norfloxacin), increases 
the probability of global resistance to these antibiotics in uropathogens (Fasugba et al., 2015). With 
respect to this phenomenon, the increase in resistance of fluoroquinolones among UPEC isolates are 
now leading to demands to counter their use as agents of the first choice (Stewardson et al., 2018) in 
agreement with Hoban et al.(2012). In this study, more than 37% of UPEC isolates were resistant to 
ciprofloxacin and levofloxacin antibiotics. Also, the rate of antimicrobial resistance towards these 
antibiotics was higher for males than for female patients (Linhares et al., 2017). In agreement with 
(Ali et al., 2019; Wagenlehner et al., 2007), we noticed older men (> 64 years) had increased risks of 
FQ-resistant (fluoroquinolones)  UTIs. Interestingly, fluoroquinolones are commonly used in male 
patients for treating UTI. Thus, it may be more difficult for male infections to eliminate due to the 
higher level of antibiotic resistance found in male-isolated strains, which can lead to persistent 
infection. Such findings were similar to earlier papers (Tabasi et al., 2015; Ali et al., 2016; Ibrahim 
et al., 2012).  
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Moreover, the prevalence of ciprofloxacin resistance in E. coli strains was 42%. We agree that 
the misuse of fluoroquinolones in the treatment of infections other than UTI in our hospital has 
resulted in high resistance to fluoroquinolone. The levels of resistance to ciprofloxacin in a multi-
center study performed on elderly patients, Escherichia Coli strains were estimated to be 30% in 
Canada and 44% in the US (Lob et al., 2016). Sanchez et al. (Sanchez et al., 2013) documented 
resistance rates of 11% in adults, and 30% in aging patients while, Fagan et al. (Fagan et al., 2015) 
recorded relatively low resistance levels toward UPEC which is 8 %. Furthermore, research carried 
out in Spain has shown that fluoroquinolone-resistant for E.coli is prevalent in older age groups 
(Nicolle et al., 2016). Also, a history of hospitalization and the use of fluoroquinolones are 
independent risk factors for developing this resistance toward antibiotics  (Das et al., 2009; Smithson 
et al., 2012).On the other hand, Ciprofloxacin and co-trimoxazole resistance associations with past 
UTI diagnosis are compatible with existing literature (Denheijer et al., 2013; Briongos-figuero et al., 
2012), and the relationship between ciprofloxacin resistance and hospitalization could be due to a 
significantly increased prevalence of resistance in hospital settings (Fasugba et al., 2015). 
      The usage of nitrofurantoin is prevalent in the treatment of ESBL-positive UPEC. 
However, in uncomplicated UTI, nitrofurantoin is prescribed only (Cortes-Penfield et al., 2017; 
Nicolle, 2016). The rate of nitrofurantoin resistance for E.coli in the current study was 1.04 %. 
However, Nitrofurantoin resistance levels were stated to be 2 percent in Fagan et al. (Norway) study 
(Fagan et al., 2015) and 7 percent in Das et al. (USA) study (Das et al., 2009). Generally, the vast 
majority of isolates remained susceptible to fosfomycin and nitrofurantoin, in terms of empirical 
therapy. Both of these are recommended antibiotics in international recommendations for 
uncomplicated UTIs (over amoxicillin-clavulanate, which is assumed to have weaker effectiveness, 
more adverse effects, and a wider cover spectrum (Gupta et al., 2010). 
        It is well established that patterns of susceptibility can differ from country to country 
geographic regions and can change with time (Ali et al., 2016). As a result, UPEC's rate of resistance 
to commonly used antimicrobials has grown over the years. As we see in this study resistance rate 
from the year 2018 to 2019 toward trimethoprim-sulfamethoxazole increases from (42.18 % to 
47.18%), cefixime (41.66 % to 48.22 %) and for augmentin (36.45 % to 40.90%) (Gupta et al., 2001). 
On the other hand, antimicrobial resistance among UPEC was growing in both community and 
hospital settings (Bonadio et al., 2001). However, carbapenems stay as the last line of treatment 
against infection caused by varieties of drug resistance that are strongly against the hydrolysis of beta-
lactamase. The reason for the increasing antibiotic resistance identified in this study may, therefore, 
be linked to the inappropriate use of antibiotics (Frère & Rigali, 2016). The other is prescribing 
inaccurate and irrational antibiotics. Thus, over-treatment with antibiotics can lead to antibiotic 
resistance and increase the persistence of extended-spectrum beta-lactamase and thus increase the rate 
of multidrug-resistant organisms. 
       Our study results indicate that in postmenopausal women with positive uropathogenic 
Escherichia coli and type 2 diabetes UTIs are typical and occur in every 1 in 3 patients. In our 
research, the prevalence of UTI observed in postmenopausal women with type 2 diabetes is equivalent 
to a study done by   (Al-Rubeaan et al., 2013) or higher than that recently reported studies (Hirji et 
al., 2012). In addition to the range of postmenopausal status, the number of variations in the 
comorbidities of patients and other variables, such as age, may explain the discrepancy. Post-
menopausal loss of estrogen is related to deregulate immunity mechanisms that are required to protect 
against E. coli adhesion to cells in the vagina. The lack of estrogen also makes the walls thinner and 
reduces the ability of the urinary tract to resist bacteria. As for diabetes itself, the clinical post-
menopausal status can contribute to other UTI-related problems, such as neuropathy leading to 
incomplete voiding of the clinical bladder and glycosuria (Funfstuck et al., 2012). Based on the results 
reported from this study antimicrobial stewardship program needs to be enforced to control antibiotic 
use and specifically decrease antibiotic resistance. Similarly, understanding of patterns of bacterial 
resistance in Escherichia coli is very relevant in the selection of empirical antimicrobial therapy to 
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5. CONCLUSION 
A- The study revealed that uropathogenic Escherichia coli ( UPEC) is the most common infectious 
disease in both the hospital and community settings and its affect a member of patients with 
different risk factors. 
B- The study detects that higher rate of resistance toward commonly used antibiotics family that 
includes Penicillin, Cephalosporin’s, Fluor quinolones, and Trimethoprim-sulfamethoxazole. 
These increase the development of AMR that has faced physicians with limited options to choose 
the correct antibiotics to treat the infections caused by MDR organisms. 
C- The study also suggests that judicious use of antibiotics, proper culture, and drug susceptibility 
monitoring and regulation of empiric antibiotics by culture and sensitivity is global conflict-
ridden in order to stop the growth of drug resistance, especially MDR, in order to limit 
complication associates with ESBL/MDR organisms related to urinary tract infection. 
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